Masimo Résultats passés
Passé contrôle des critères 5/6
Les bénéfices de Masimo ont diminué à un taux annuel moyen de -32.3%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en à 13.6% par an. Les revenus ont augmenté de en à un taux moyen de 5.8% par an. Le rendement des capitaux propres de Masimo est 27.5% et ses marges nettes sont de 13.9%.
Informations clés
-32.28%
Taux de croissance des bénéfices
-31.48%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 8.90% |
| Taux de croissance des recettes | 5.75% |
| Rendement des fonds propres | 27.48% |
| Marge nette | 13.91% |
| Dernière mise à jour des bénéfices | 04 Apr 2026 |
Mises à jour récentes des performances passées
Recent updates
MASI: Cash Deal Terms And Legal Outcomes Will Shape Future Returns
Analysts held Masimo's fair value estimate steady at $180 per share, with only small tweaks to discount rate, growth, margin, and P/E assumptions as they factor in the agreed $180 per share cash acquisition by Danaher and recent shifts in research coverage and ratings. Analyst Commentary Recent research coverage on Masimo has shifted toward a more balanced stance after the agreed cash acquisition by Danaher at US$180 per share, with several firms resetting ratings and price targets around the deal terms.MASI: Danaher Cash Offer And Legal And Deal Completion Risks Will Dominate
The analyst fair value estimate for Masimo has been adjusted from $177 to $180, with analysts pointing to the agreed $180 per share cash acquisition by Danaher as the key anchor for updated price targets and ratings. Analyst Commentary Recent research on Masimo has shifted from growth driven valuation debates to a focus on the agreed US$180 per share cash offer from Danaher as the primary reference point for fair value and ratings.MASI: Danaher Cash Offer And Legal Outcomes Will Steer Deal Path
The analyst price target for Masimo has been trimmed by about $1.60 to $177.00, as analysts factor in a slightly higher discount rate and a modestly lower future P/E, while aligning expectations with the $180 per share cash acquisition offer from Danaher. Analyst Commentary Recent research on Masimo has become highly focused on the agreed cash acquisition by Danaher at $180 per share, with most coverage shifting from long term growth narratives to deal related outcomes and near term valuation anchor points.MASI: Danaher Cash Offer And Patent Rulings Will Shape Deal Outcome
Analysts kept Masimo's fair value estimate steady at $178.60 while aligning their price targets around the agreed $180 per share cash acquisition by Danaher, with recent rating changes reflecting the view that any potential upside is now largely tied to the deal closing as planned. Analyst Commentary Recent research on Masimo centers on the agreed US$180 per share cash offer from Danaher, with ratings and targets now clustered around that level.MASI: Danaher Cash Deal And Legal Overhang Will Frame Future Returns
The updated analyst price target for Masimo edges down by $0.15 to $178.60, as analysts anchor their views to Danaher's agreed $180 per share cash acquisition and recent rating moves to Neutral or No Rating. Analyst Commentary Recent research around Masimo has centered on the agreed US$180 per share cash acquisition by Danaher, with most analysts reframing their views around deal completion rather than standalone upside or downside.MASI: Danaher Cash Buyout Will Define Future Returns And Key Risks
Analysts have trimmed their Masimo fair value estimate from $183.13 to $178.75 to align expectations with the agreed $180 per share cash acquisition by Danaher. This shift is reflected in new Hold and Neutral ratings that are centered around the $180 level.Masimo: Danaher Acquisition Saves The Company From Lackluster Performance
Summary Masimo Corporation agreed to be acquired by Danaher for $180/share, valuing MASI at $9.9B. The acquisition offers a strong strategic fit, combining MASI's non-invasive oximetry with DHR's invasive diagnostics for comprehensive acute care solutions. Shareholders benefit from a 34% stock price surge and a potential 2.8% spread to deal close, with minimal market risk. Holding MASI shares until the deal closes offers a relatively safe, low-stress return, though opportunity cost and regulatory risk remain. Read the full article on Seeking AlphaMASI: Renewed Philips Partnership Will Drive Outperformance Despite Market Challenges
Analysts have adjusted their price target for Masimo downward from approximately $188 to $183. This change is attributed to shifts in revenue growth estimates and a strengthening profit margin following recent partnership developments and ongoing market challenges.Is Masimo Corporation (NASDAQ:MASI) Potentially Undervalued?
Masimo Corporation ( NASDAQ:MASI ), might not be a large cap stock, but it received a lot of attention from a...Calculating The Fair Value Of Masimo Corporation (NASDAQ:MASI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Masimo fair value estimate is US$136 Masimo's US$154 share...Is Masimo (NASDAQ:MASI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is It Time To Consider Buying Masimo Corporation (NASDAQ:MASI)?
Masimo Corporation ( NASDAQ:MASI ), is not the largest company out there, but it saw significant share price movement...Masimo: Priced Dearly Given Uncertainty
Summary Masimo Corporation, a mid-cap healthcare firm, has a new CEO and is navigating considerable uncertainty. Some aspects of the company's divestiture of its consumer business are still unclear. Despite this, the stock is generally well liked within the analyst firm community, following solid Q4 results. An analysis around Masimo Corporation follows in the paragraphs below. Read the full article on Seeking AlphaMasimo: A Stellar Performance After The Dust Has Settled
Summary Masimo's proxy fight and Sound United acquisition distracted from the core business, but resolution and focus on healthcare are driving value and momentum. Shares surged over 50% since July due to strong Q2 results and improved earnings guidance, despite ongoing challenges and leadership changes. Current valuations are demanding, suggesting an opportune time for profit taking, while I maintain a position for long-term growth potential. Divesting Sound United could reduce debt, enhancing focus on the core med-tech business with promising double-digit organic growth. Read the full article on Seeking AlphaMasimo Corporation: Too Much Uncertainty For Now
Summary Masimo Corporation's stock has underperformed, with shares down 6% versus SPY's 15% increase, due to mixed margins and lack of meaningful catalysts. The company's financials show low ROA, ROE, and ROTC, with tight margins and a concerning interest coverage ratio of 2.6x. The sale of Sound United and recent partnerships with Google and Qualcomm offer potential, but the future growth sustainability remains uncertain. Internal management struggles and recent board shakeup add to the volatility, making me cautious and opting to stay on the sidelines for now. Read the full article on Seeking Alpha
Sensors Surge And Decisive Shifts Set To Soar In Healthcare Triumph
Increased hospital admissions and successful hospital conversions to Masimo products are anticipated to continue driving healthcare revenue growth.Ventilation des recettes et des dépenses
Comment Masimo gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 04 Apr 26 | 1,559 | 217 | 517 | 123 |
| 03 Jan 26 | 1,527 | 208 | 511 | 126 |
| 27 Sep 25 | 2,182 | -240 | 749 | 203 |
| 28 Jun 25 | 2,154 | -270 | 770 | 210 |
| 29 Mar 25 | 1,428 | 31 | 516 | 142 |
| 28 Dec 24 | 1,395 | 16 | 518 | 146 |
| 28 Sep 24 | 1,576 | 115 | 538 | 152 |
| 29 Jun 24 | 1,711 | 101 | 558 | 161 |
| 30 Mar 24 | 1,823 | 92 | 588 | 163 |
| 30 Dec 23 | 1,276 | 108 | 451 | 131 |
| 30 Sep 23 | 2,116 | 89 | 690 | 192 |
| 01 Jul 23 | 2,187 | 116 | 707 | 198 |
| 01 Apr 23 | 2,297 | 118 | 728 | 206 |
| 31 Dec 22 | 2,036 | 144 | 641 | 191 |
| 01 Oct 22 | 1,746 | 171 | 559 | 170 |
| 02 Jul 22 | 1,505 | 191 | 487 | 153 |
| 02 Apr 22 | 1,244 | 223 | 408 | 139 |
| 01 Jan 22 | 1,239 | 230 | 395 | 137 |
| 02 Oct 21 | 1,207 | 232 | 382 | 136 |
| 03 Jul 21 | 1,177 | 224 | 371 | 129 |
| 03 Apr 21 | 1,173 | 229 | 376 | 126 |
| 02 Jan 21 | 1,144 | 240 | 369 | 119 |
| 26 Sep 20 | 1,096 | 223 | 361 | 110 |
| 27 Jun 20 | 1,047 | 222 | 351 | 106 |
| 28 Mar 20 | 976 | 211 | 330 | 99 |
| 28 Dec 19 | 938 | 196 | 315 | 93 |
| 28 Sep 19 | 913 | 190 | 306 | 91 |
| 29 Jun 19 | 895 | 198 | 297 | 87 |
| 30 Mar 19 | 877 | 197 | 289 | 83 |
| 29 Dec 18 | 858 | 194 | 285 | 81 |
| 29 Sep 18 | 843 | 139 | 290 | 76 |
| 30 Jun 18 | 826 | 118 | 284 | 71 |
| 31 Mar 18 | 807 | 119 | 280 | 67 |
| 30 Dec 17 | 790 | 125 | 273 | 65 |
| 30 Sep 17 | 766 | 348 | 271 | 60 |
| 01 Jul 17 | 740 | 340 | 263 | 61 |
| 01 Apr 17 | 720 | 325 | 260 | 59 |
| 31 Dec 16 | 713 | 311 | 255 | 58 |
| 01 Oct 16 | 672 | 109 | 255 | 58 |
| 02 Jul 16 | 657 | 101 | 257 | 57 |
| 02 Apr 16 | 640 | 90 | 254 | 55 |
| 02 Jan 16 | 623 | 83 | 253 | 56 |
| 03 Oct 15 | 623 | 80 | 244 | 58 |
| 04 Jul 15 | 613 | 76 | 246 | 58 |
Des revenus de qualité: MASI a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de MASI sont plus élevées que l'année dernière MASI. (13.9%) sont plus élevées que l'année dernière (0.8%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de MASI ont diminué de 32.3% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de MASI au cours de l'année écoulée ( 1792.8% ) dépasse sa moyenne sur 5 ans ( -32.3% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices MASI au cours de l'année écoulée ( 1792.8% ) a dépassé celle du secteur Medical Equipment 14.8%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de MASI ( 27.5% ) est considéré comme élevé.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/24 13:09 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/04/04 |
| Revenus annuels | 2026/01/03 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Masimo Corporation est couverte par 22 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Polark | Baird |
| Charley Jones | Barrington Research Associates, Inc. |
| Ravi Misra | Berenberg |